WWP
ALNY icon

WR Wealth Planners’s Alnylam Pharmaceuticals ALNY Stock Holding History

WR Wealth Planners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.41K Buy
6
+2
+50% +$526 ﹤0.01% 894
2024
Q3 		$1.1K Buy
+4
New +$1.04K ﹤0.01% 966

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

WR Wealth Planners's ALNY Position: Q4 2024 in Review

WR Wealth Planners increased its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q4 2024, buying an estimated $526 and bringing the position to 6 shares worth $1.41K. The position accounts for ﹤0.01% of the portfolio, ranked #894.

WR Wealth Planners first reported a position in ALNY in Q3 2024 and has held it in 2 quarters since. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • WR Wealth Planners held 6 shares of Alnylam Pharmaceuticals worth $1.41K as of Q4 2024.
  • WR Wealth Planners bought 2 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $526.
  • Alnylam Pharmaceuticals made up ﹤0.01% of WR Wealth Planners's portfolio in Q4 2024, its #894 holding.
  • WR Wealth Planners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on WR Wealth Planners's 13F filing for Q4 2024, filed 5 Feb 2025.